Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01QGX
|
|||
| Former ID |
DCL000873
|
|||
| Drug Name |
Lurasidone hydrochloride
|
|||
| Synonyms |
Lurasidone HCl; SM 13496; Lurasidone hydrochloride (USAN); MK-3756; SM-13496; SMP-13496; N-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinylmethyl)-1-cyclohexylmethyl)-2,3-bicyclo(2.2.1)heptanedicarboximide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Schizophrenia [ICD-11: 6A20] | Approved | [1], [2], [3], [4] | |
| Company |
Sumitomo
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C28H37ClN4O2S
|
|||
| Canonical SMILES |
C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O.Cl
|
|||
| InChI |
1S/C28H36N4O2S.ClH/c33-27-24-18-9-10-19(15-18)25(24)28(34)32(27)17-21-6-2-1-5-20(21)16-30-11-13-31(14-12-30)26-22-7-3-4-8-23(22)35-29-26;/h3-4,7-8,18-21,24-25H,1-2,5-6,9-17H2;1H/t18-,19+,20-,21-,24+,25-;/m0./s1
|
|||
| InChIKey |
NEKCRUIRPWNMLK-SCIYSFAVSA-N
|
|||
| CAS Number |
CAS 367514-88-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
16247346, 30417284, 47362895, 51026536, 57399659, 103068778, 103080863, 104253152, 117591937, 123051051, 134224709, 134339501, 135187871, 135692869, 136351322, 137892911, 160645972, 162011722, 162517092, 175265796, 175427100, 187051764, 223668806, 224768364, 226972568, 249821695, 249866658, 252110201, 252215721, 252448605
|
|||
| ChEBI ID |
CHEBI:70732
|
|||
| ADReCS Drug ID | BADD_D01330 ; BADD_D01331 | |||
| SuperDrug ATC ID |
N05AE05
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7461). | |||
| REF 2 | Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. | |||
| REF 3 | Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther. 2010 Jul;334(1):171-81. | |||
| REF 4 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.